Corey Goodman, Ph.D. is co-founder of Tallac Therapeutics™. He also serves as chair of the board of directors. Dr. Goodman is a Managing Partner of venBio Partners.

Dr. Goodman is a scientist, educator, and entrepreneur. He spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at U.C. Berkeley (Dept. of Molecular and Cell Biology), where he was a Howard Hughes Medical Institute Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. He is currently Adjunct Professor of Neuroscience in the Wills Neuroscience Institute at U.C. Berkeley. Dr. Goodman is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, Dawson Prize in Genetics from Trinity College Dublin, and the Gruber Neuroscience Prize.

Dr. Goodman co-founded seven biotechnology companies (the first being Exelixis), and led one of them (Renovis) as President and CEO from a private to public company until its acquisition. He was recruited to be President and founder of Pfizer’s Biotherapeutics and Bioinnovation Center and a member of Pfizer’s executive leadership team.

Dr. Goodman is Chair of the Board of ALX Oncology, Tallac, and Second Genome. He is a member of the Board of NFlection and Attralus. He chaired Labrys Biologics until its acquisition by Teva. Amongst his many public policy roles, Dr. Goodman is a member of the University of California Innovation Council, a member of the board of the Pacific Institute, and former Chair of both the California Council on Science and Technology (advising the California governor and state legislature) and the National Research Council’s (NAS) Board on Life Sciences (advising the federal government).